Genetic Technologies (Genetic Technologies) Debt-to-Revenue : N/A (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Genetic Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.20 Mil. Genetic Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.06 Mil. Genetic Technologies's annualized Revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

Genetic Technologies Debt-to-Revenue Historical Data

The historical data trend for Genetic Technologies's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Debt-to-Revenue Chart

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Revenue

Get a 7-Day Free Trial

47.43

1.68

0.10

0.06

Genetic Technologies Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Genetic Technologies's Debt-to-Revenue

For the Diagnostics & Research subindustry, Genetic Technologies's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Debt-to-Revenue falls into.

Genetic Technologies Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Genetic Technologies's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.204	+	0.154)	/	5.83
	=	0.06

Genetic Technologies's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.199	+	0.056)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Genetic Technologies Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.